Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.49 |
| ▸ | CASP6 | P55212 | 17/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 17/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878064 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL20870231 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL11896297 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL2878062 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL11896299 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL11896298 | 1.00 | CASP3 (0.49) | CASP3CASP6CASP8CTSD | |
| SCHEMBL13260540 | 0.97 | CASP3 (0.47) | CASP3CASP6CASP8CTSD | |
| SCHEMBL17494191 | 0.94 | CASP3 (0.54) | CASP3CASP6CASP8 | |
| SCHEMBL17494192 | 0.94 | CASP3 (0.54) | CASP3CASP6CASP8 | |
| SCHEMBL17494193 | 0.94 | CASP3 (0.54) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196892-A1 | NOVEL CASPASE-2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20100184703-A1 | USE OF PEPTIDE DERIVATIVES FOR TREATING PATHOLOGIES RESULTING FROM ISCHEMIA | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-22 | — | — | US | disclosed |
| US-20100184703-A1 | USE OF PEPTIDE DERIVATIVES FOR TREATING PATHOLOGIES RESULTING FROM ISCHEMIA | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196892-A1 | NOVEL CASPASE-2 INHIBITORS | CASP2, CASP1, CASP9 | CASP3 5/4885CASP6 8/4885CASP8 13/4885 |
| US-20100184703-A1 | USE OF PEPTIDE DERIVATIVES FOR TREATING PATHOLOGIES RESULTING FROM ISCHEMIA | CASP2, TNNI3, TNNT2 | CASP3 6/4885CASP6 21/4885CASP8 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.